Filing excerpt
Beginning in July 2025, we initiated voluntary corrections for the Novum LVP due to the potential for over- and under-infusion related to set misloading, as well as certain software anomalies. The U.S. Food and Drug Administration (FDA) classified these voluntary corrections as Class I recalls.